Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer

Published:2023-09 Issue:9 Volume:18 Page:1199-1208
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Jung Hyun-Ae,Ku Bo Mi,Kim Yeon Jeong,Park Sehhoon,Sun Jong-Mu,Lee Se-Hoon,Ahn Jin Seok,Cho Jong Ho,Kim Hong Kwan,Choi Yong Soo,Choi Yoon-La,Shin Sun Hye,Jeong Byeong-Ho,Um Sang-Won,Kim Hojoong,Kim Kyunga,Ahn Myung-Ju,Kim Jingook

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer;Goldstraw;J Thorac Oncol,2016

2. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer;Arriagada;N Engl J Med,2004

3. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

4. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups;Strauss;J Clin Oncol,2008

5. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study;Zhong;Lancet Oncol,2018

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrochemical sensing technology based on a ligation-initiated LAMP-assisted CRISPR/Cas12a system for high-specificity detection of EGFR E746–A750 deletion mutation;Biosensors and Bioelectronics;2024-11

2. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-09

3. Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies;Cancers;2024-08-06

4. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

5. Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer;Future Oncology;2024-07-29